PMID- 37629741
OWN - NLM
STAT- MEDLINE
DCOM- 20230828
LR  - 20230829
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 59
IP  - 8
DP  - 2023 Aug 11
TI  - Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial 
      Carcinoma.
LID - 10.3390/medicina59081452 [doi]
LID - 1452
AB  - This study aimed to evaluate the diagnostic and prognostic roles of GATA-binding 
      protein 3 (GATA3) immunohistochemistry in urothelial carcinoma (UC) using a 
      meta-analysis. We investigated GATA3 immunohistochemical expression rates and 
      performed a subgroup analysis based on tumor site, study location, and 
      histological subtypes. The overall survival rates of patients with GATA3-positive 
      and -negative UC were compared. The estimated GATA3 expression rate was 0.748 
      (95% confidence interval [CI]: 0.704-0.787). GATA3 expression rates in the 
      urinary bladder and urinary tract were 0.775 (95% CI: 0.727-0.818) and 0.614 (95% 
      CI: 0.426-0.774), respectively. The GATA3 expression rates of noninvasive and 
      invasive UCs were 0.965 (95% CI: 0.938-0.980) and 0.644 (95% CI: 0.581-0.702), 
      respectively. In invasive UCs, there was a significant difference in GATA3 
      expression between non-muscular invasion and muscular invasion subgroups (0.937, 
      95% CI: 0.883-0.967 vs. 0.753, 95% CI: 0.645-0.836). GATA3 expression was the 
      highest in the microcytic subtype among the histologic subtypes (0.952, 95% CI: 
      0.724-0.993). There was a significant correlation between GATA3 expression and 
      better prognosis (hazard ratio: 0.402, 95% CI: 0.311-0.521). Taken together, 
      GATA3 expression significantly correlated with low-stage and better prognosis in 
      UC. GATA3 expression is highly variable across histological subtypes, and one 
      should be careful while interpreting GATA3 expression.
FAU - Yoo, Daeseon
AU  - Yoo D
AD  - Department of Urology, Daejeon Eulji University Hospital, Eulji University School 
      of Medicine, Daejeon 35233, Republic of Korea.
FAU - Min, Kyueng-Whan
AU  - Min KW
AUID- ORCID: 0000-0002-4757-9211
AD  - Department of Pathology, Uijeongbu Eulji Medical Center, Eulji University School 
      of Medicine, Uijeongbu-si 11759, Republic of Korea.
FAU - Pyo, Jung-Soo
AU  - Pyo JS
AUID- ORCID: 0000-0003-0320-8088
AD  - Department of Pathology, Uijeongbu Eulji Medical Center, Eulji University School 
      of Medicine, Uijeongbu-si 11759, Republic of Korea.
FAU - Kim, Nae Yu
AU  - Kim NY
AUID- ORCID: 0000-0002-0461-6385
AD  - Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University 
      School of Medicine, Uijeongbu-si 11759, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20230811
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (GATA3 protein, human)
RN  - 0 (GATA3 Transcription Factor)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Transitional Cell/diagnosis
MH  - *Urinary Bladder Neoplasms/diagnosis
MH  - Immunohistochemistry
MH  - Prognosis
MH  - Urinary Bladder
MH  - GATA3 Transcription Factor
PMC - PMC10456966
OTO - NOTNLM
OT  - GATA3
OT  - immunohistochemistry
OT  - meta-analysis
OT  - overall survival
OT  - urothelial carcinoma
COIS- The authors declare no conflict of interest.
EDAT- 2023/08/26 10:44
MHDA- 2023/08/28 06:43
PMCR- 2023/08/11
CRDT- 2023/08/26 01:20
PHST- 2023/07/16 00:00 [received]
PHST- 2023/08/10 00:00 [revised]
PHST- 2023/08/10 00:00 [accepted]
PHST- 2023/08/28 06:43 [medline]
PHST- 2023/08/26 10:44 [pubmed]
PHST- 2023/08/26 01:20 [entrez]
PHST- 2023/08/11 00:00 [pmc-release]
AID - medicina59081452 [pii]
AID - medicina-59-01452 [pii]
AID - 10.3390/medicina59081452 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2023 Aug 11;59(8):1452. doi: 10.3390/medicina59081452.